Citations

Clear

904 citation(s) found for "Gordon, S".

Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
Colbert, Sarah M. C. , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud, Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I, Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris, Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette, Euler, Sebastian, Falkai, Peter, Fanelli, Giuseppe, Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip, Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs, Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Holla, Bharath, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary S, Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A, Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pisanu, Claudia, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas G, Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus, Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E, Docherty, Anna R. , Mullins, Niamh , Roberts, Gloria , Pisanu, Claudia , Holla, Bharath , Fanelli, Giuseppe , Ruderfer, Douglas , Docherty, Anna R , Mullins, Niamh , Pisanu, Claudia , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud R. , Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I , Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris , Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette , Euler, Sebastian, Falkai, Peter , Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip , Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs , Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary Sophia , Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A. , Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas , Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus , Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E

Mayo Clinic

No container title available | October 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.22.25338076 | PMID 41282879 Get It

ABSTRACT Suicidality contributes substantially to global morbidity and mortality, yet despite its heritability, its biological etiology remains largely elusive. We conducted multi-ancestry genome-wide association study meta-analyses of suicidal ideation (259,747 cases), suicide attempt (64,993 cases), suicide death (9,197 cases), and suicidal behavior (suicide attempt/ death, 75,300 cases), across 54 cohorts (e.g., the Psychiatric Genomics Consortium, Million Veteran Program, UK Biobank). We identified 77 significant loci across meta-analyses, including 59 previously unreported for suicidality. SNP-based heritability ranged from 2.0-6.7% and there were strong, yet incomplete, genetic correlations between suicidality phenotypes (0.70-0.88). Fine-mapping prioritized putative causal SNPs and 20 credible genes. Enrichment analyses implicated synaptic pathways and neuronal populations predominantly in subcortical brain regions (e.g., amygdala excitatory, medium spiny, hippocampal CA1-3). Together, these findings establish suicidality as a polygenic set of traits with both shared and distinct genetic influences, providing a foundation for future studies of suicide biology and etiology.
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study
Lass, Jonathan H. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Beck, Roy W., Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy N. , Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, Neal, Rosselson, Marie, Nykaza, Jim, Jurkunas, Ula V., Venkateswaran, Nandini, Cheung, Michael K., Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, G, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Hardten, David R., Reeves, Sherman, Dreyer, Allison, Mack, Megan, Hamill, M. Bowes , Nguyen, Jessica, Koo, Ellen, Stanfield, Ryan, Greenwood, Michael, Ernst, L, Messer, Brooke, Risbrudt, Nick, Stofferahn, Seth, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Szczotka-Flynn, Loretta, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Kollman, Craig, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Lê, Jimmy T. , Redford, Maryann , Arafah, Baha M. , Greiner, Mark, Johnson, Paula C, Keeler, D. K., Monnier, Vincent M. , Titus, Michael, Verdier, David, Soper, Mark, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Sengupta, Pratim , Wadleigh, Garth, Greiner, Mark A. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hood, Christopher, Sáles, Christopher S. , Sinkey, Chris, Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Croasdale, Christopher, Brown, Gayle Waldheim, Epstein, Rachel H. , Vaidya, Neal, Jurkunas, Ula V. , Cheung, Michael, Prasad, Elizabeth, Toti, Gwen, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Reeves, Sherman, Dreyer, Allison, Mack, Megan, Nguyen, Jessica, Greenwood, Michael, Messer, Brooke, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Schmidt, Gregory A. , Lass, Jonathan, Lass, Jonathan, Price, Marianne O. , Szczotka-Flynn, Loretta, Richards, Leslie, Bauza, Colleen, Beck, Roy W. , Kollman, Craig, McCarthy, Chris, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Greiner, Mark, Johnson, Paula, Titus, Michael, Verdier, David, Soper, Mark, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dingess, Ryan, Sengupta, Paromita

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1053

10.1001/jamaophthalmol.2025.4261 | PMID 41105099 Get It

Importance The effect of cornea donor diabetes on endothelial cell density (ECD) and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. Objective To determine whether endothelial cell loss (ECL) and morphometric changes 1 year after successful DMEK are related to cornea donor’s diabetes status. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2024 at 28 US clinical sites (46 surgeons) and 13 eye banks. Included in the trial were the eyes of recipients (some of whom received tissue from donors without diabetes and others who received tissue from donors with diabetes) who underwent successful DMEK, primarily for Fuchs endothelial corneal dystrophy, and had at least 1 analyzable postoperative endothelial image. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure to achieve an approximate 2:1 distribution. Main Outcomes and Measures ECD, ECL, coefficient of variation in cell area (CV), and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. Results A total 1274 eyes of 982 recipients (mean [SD] age, 70 [8] years; 569 female [57.9%]; 816 [64.1%] with tissue from donors without diabetes and 458 [35.9%] with tissue from donors with diabetes) were included in the study. Preoperatively, mean (SD) central ECD in tissue from donors without diabetes and with diabetes were 2676 (290) cells/mm 2 and 2671 (286) cells/mm 2 , respectively. At 1 year, mean (SD) ECL was 28.3% (16.1%) and 28.0% (17.0%), in the donor groups without and with diabetes, respectively (adjusted mean difference = −0.4%; 95% CI, −2.3% to 1.4%), resulting in a mean (SD) 1-year ECD of 1927 (498) cells/mm 2 and 1920 (496) cells/mm 2 , respectively (adjusted mean difference = 10 cells/mm 2 ; 95% CI, −36 to 56; P = .95). No difference in ECD at 1 year associated with diabetes severity was noted ( P = .97). Mean (SD) CV did not differ at 1 year between the 2 groups of eyes (31.5% [4.1%] vs 31.4% [4.1%]; adjusted mean difference = −0.4%; 95% CI, −0.9% to 0.1%; P = .51), and mean (SD) HEX did not differ at 1 year between the 2 groups of eyes (57.7% [5.8%] vs 57.2% [5.8%]; adjusted mean difference = 0.1%, 95% CI, −0.8% to 0.9%; P = .33). Conclusions and Relevance This randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes status. With comparable 1-year graft success with tissue from donors with and without diabetes demonstrated in this trial, these findings support the use of corneas from donors with diabetes for endothelial keratoplasty procedures. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate
Price, Francis W. , Szczotka‐Flynn, Loretta , Bauza, Colleen , Reed, Zachariah W., Arafah, Baha M. , Greiner, Mark A. , Johnson, Paula, Keeler, Devon B., Pramanik, Sudeep, Soper, Mark, Terry, Mark A., Titus, Michael S. , Verdier, David D. , Kollman, Craig, Lass, Jonathan H. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lynn, A. G., Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy, Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James L. , Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, N. N., Nykaza, Jim, Venkateswaran, Nandini, Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, Gwen, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark D., Hardten, David R., Reeves, Sherman W., Dreyer, Allison, Mack, Megan, Hamill, Mark, Nguyen, Jessica , Stanfield, Ryan, Greenwood, Michael , Ernst, Lindsay, Risbrudt, Nick, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Beck, Roy, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann , Lê, Jimmy T. , Redford, Maryann , Arafah, Baha, Greiner, Mark, Keeler, Devon, Monnier, Vincent M. , Titus, Michael, Verdier, David, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad I. , Pramanik, Sudeep , Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Wadleigh, Garth, Price, Marianne O. , Mian, Shahzad I. , Patel, Sanjay V. , Pramanik, Sudeep, Titus, Michael S., Beck, Roy W. , Lass, Jonathan H., Group, Diabetes Endothelial Keratoplasty Study, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hardtke, Elainey, Hood, Christopher, Shapiro, Jeremy, Sáles, Christopher S. , Leavy, Lisa, Gordon, DJ, Fox, Jenni, Coonfield, Kristy, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Crosser, Vicki, Croasdale, Christopher, Brown, Gayle Waldheim, Evans, Que, Epstein, Rachel H. , Nykaza, Jim, Jurkunas, Ula V. , Cheung, Michael, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Mack, Megan, Hamill, M. Bowes, Nguyen, Jessica, Koo, Ellen H. , Stanfield, Ryan, Risbrudt, Nick, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Schmidt, Gregory A. , Elbanhawy, Lindsey, Statz, Brianne, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Richards, Leslie, Spruill, Rashad, Bauza, Colleen, Beck, Roy, McCarthy, Chris, Reed, Zachariah, Arafah, Baha, Greiner, Mark, Titus, Michael, Verdier, David, Velhuisen, Paul Van, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Price, Francis, Terry, Mark, Sell, David, Barton, Glenn, Das, Pravamaya, Dingess, Ryan, Madere, Mark, Sengupta, Partha Pratim , Wadleigh, Garth

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1043

10.1001/jamaophthalmol.2025.4253 | PMID 41105094 Get It

Importance If the success of Descemet membrane endothelial keratoplasty (DMEK) is not affected by whether the donor has diabetes, then the donor pool should expand. Objective To determine whether the 1-year DMEK success rate is affected by the presence of diabetes in the donor. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2025 at 28 clinical sites (46 surgeons), with donor corneas provided by 13 eye banks in the US. Included in the study were individuals undergoing low to moderate risk DMEK (95% for Fuchs endothelial corneal dystrophy). Study data were analyzed from April to September 2025. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable with randomization) to achieve an approximate 2:1 distribution, respectively. Main Outcomes and Measures Graft success at 1 year Results A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 female [57.5%]) were included in the study. The 1-year cumulative probability of graft success was 96.3% (95% CI, 95.0%-97.5%) among 912 study eyes (64.2%) receiving tissue from donors without diabetes and 97.1% (95% CI, 95.5%-98.4%) among 509 study eyes (35.8%) receiving tissue from donors with diabetes (difference between groups = 0.7 percentage points; 95% CI, −1.2 to 2.6; P = .63). The 1-year cumulative probability of graft success was 96.5% (95% CI, 93.6%-98.9%) in the mild donor diabetes severity subgroup (n = 173) and 97.3% (95% CI, 95.4%-98.8%) in the moderate to severe donor diabetes severity subgroup (n = 336), using a diabetes severity rating scale based on medical history. The rates of primary donor failure, early failure related to surgical complications, and subsequent failure were as follows: 2.5% (23 of 912), 0.7% (6 of 912), and 0.3% (3 of 912), respectively, in recipients of tissue from a donor without diabetes, and 2.6% (13 of 509), 0.4% (2 of 509), and 0%, respectively, among recipients of tissue from a donor with diabetes. There were no failures due to graft rejection. Conclusions and Relevance The 1-year success rate in eyes undergoing DMEK with successfully prepared tissue was very high regardless of donor diabetes status. These results, supported by the separately reported finding that endothelial cell loss and cornea morphometry after 1 year were not affected by donor diabetes status, provide strong support for having no restrictions on the use of tissue from donors with diabetes for DMEK. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer
Ottaviani, Daniela , Ola, Mihaela , Hickey, Seán , Jagušt, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona T., Fallon, Ramón, Daly, Gordon, Hudson, Lance, Kalsi, Shannon, Shovlin, Stephen, Powell, Aoibhín , Bahl, Ash , Ainscow, Ed, Oesterreich, Steffi , Couch, Fergus J. , Hill, Arnold D., Varešlija, Damir , Allotta, Alessandra , Hickey, Seán , Jagust, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona , Fallon, Ramón , Daly, Gordon , Hegarty, Aisling , Hudson, Lance , Sheehan, Katherine , Kalsi, Shannon , Shovlin, Stephen , Powell, Aoibhín , Ainscow, Ed , Oesterreich, Steffi , Lee, Adrian V , Hill, Arnold D K , Varešlija, Damir , Young, Leonie , Chaibi, Yasmine Maati, Lee, Adrian V. , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 14, 2025 | Volume: 118 | Issue: 3 | Pages: 404-421

10.1093/jnci/djaf295 | PMID 41092317 Get It

Abstract Background Cyclin-dependent kinase 12 (CDK12) regulates general gene transcription elongation and plays multiple roles in RNA splicing, DNA damage-response, cell cycle, and genomic stability. However, transcriptional partners that guide CDK12-specific gene programs have not been identified. Genomic alterations in CDK12 have been observed in multiple cancers, exhibiting both pro-tumorigenic and tumor-suppressive functions, suggesting a context-dependent mechanism of action. Methods CDK12 copy number alterations and gene expression levels were analyzed in matched primary and brain metastatic patient tumors. Clinical significance was assessed by immunohistochemistry in a large cohort of primary breast cancer patient tumors. RNA sequencing, ChIP sequencing, and molecular studies were conducted to explore CDK12’s mechanism of action, and pharmacological studies were performed both in vitro and in vivo using models of advanced (endocrine-resistant and metastatic) estrogen receptor positive (ER+) disease. Results CDK12 amplifications and gene overexpression were observed in brain metastatic tumors. In ER+ primary patient tumors, high CDK12 protein expression was significantly associated with poor overall survival, particularly within the ER+/HER2-negative group. In ER+ endocrine resistant models, CDK12 regulated estrogen signaling pathways, with ER/MED1 identified as the master transcriptional complex directing CDK12-specific pro-tumorigenic gene programs. Pharmacological inhibition of CDK12 significantly reduced viability in endocrine resistant and metastatic cell and organoid models in vitro, and decreased metastatic spread in vivo. Conclusion This work describes a novel mechanism for CDK12, suggesting a potential vulnerability in ER+ breast cancer. These findings provide a basis for further investigation into the role of CDK12 inhibition as a therapeutic approach, particularly in advanced disease settings.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Rabinovitch, Rachel , Roberts, Kenneth B. , Saito, Naoyuki G. , Smith, Stephen D. , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Kline, Justin Paul , Landsburg, Daniel J. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0048 | PMID 41067277 Get It

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody–drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor–based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Analyzing the Practice of Pediatric Infectious Diseases to Identify the Knowledge Tested on ABP Board Certification Exams
Elward, Alexis, Dehority, Walter , Kainth, Mundeep K. , Schein, Rebecca, Schutze, Gordon E., Ristagno, Elizabeth H. , Dehority, Walter N , Kainth, Mundeep K , Ristagno, Elizabeth H , Dwyer, Andrew C, Schein, Rebecca S

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | October 3, 2025 | Volume: 14 | Issue: 10 | Pages: No page available

10.1093/jpids/piaf090 | PMID 41042216 Get It

Abstract Background To ensure the Pediatric Infectious Diseases (ID) Certifying Examination remains aligned with current clinical practice, the American Board of Pediatrics (ABP) conducted a comprehensive practice analysis to update the exam content outline. Methods A panel of 9 pediatric ID physicians identified 34 core tasks across 5 performance domains to guide revisions to the existing outline. The panel identified relevant, testable knowledge areas aligned with these tasks and organized them into 22 domains and 186 initial subdomains. A nationwide validation survey of board-certified pediatric ID physicians collected relevance ratings and feedback on missing or outdated topics and suggested exam weights, which were used to guide further revisions. Subsequently, the pediatric ID subboard conducted an item reclassification process, which resulted in additional refinement. Results The final content outline comprises 22 domains and 196 subdomains, with updated domain weights to better reflect the clinical landscape. Notably, domains such as cardiovascular, bone and joint, and urologic infections increased in weight, while antimicrobial principles decreased. Conclusions This rigorous, inclusive process strengthens the exam’s content validity and supports the ABP’s goal of certifying physicians who possess the knowledge needed to deliver safe and effective care.
Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, on the behalf of the EPI Study, Baz, Maher, Hachem, Ramsey R. , Byers, Derek E. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, on the behalf of the EPI Study

Mayo Clinic

Transplantation | October 1, 2025 | Volume: 110 | Issue: 2 | Pages: e481-e491

10.1097/tp.0000000000005515 | PMID 41032890 Get It

Background. The spirometric response to standard-of-care (SOC) immunosuppressive therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsely reported in the literature. Data from a Medicare-approved Registry were analyzed to characterize the effectiveness/durability of a wide range of SOC interventions to manage the decline of lung function and to validate the study spirometric criteria for initiation of rescue therapy. Methods. Lung transplant recipients with refractory BOS at 21 US collaborating centers were enrolled in the Registry. Data included both nonspirometric (eg, demographic, Immunosuppressive Regimens for management of BOS) and spirometric parameters (ie, forced expiratory volume in 1 s [FEV 1 ] measurements and derived indices). The utility of study FEV 1 criteria for treatment (ie, statistically significant rate of FEV 1 decline >30 mL/mo) was evaluated by comparing the spirometric course between participants who met or did not meet this criterion. Results. Only 21% of participants treated with SOC therapy had >50% decrease (76 ± 25% decrease) in the rate of FEV 1 decline. Although 51% of participants had a partial response (rate of FEV 1 decline decreased on average 71%), 49% of participants had a substantial increase (mean increase 224%). The FEV 1 criterion for treatment was able to identify 19% of participants (48/258) who achieved durable stabilization (ie, nonsignificant rate of FEV 1 <30 mL/mo) with SOC therapy. Conclusions. Patients with BOS have a widely variable response to SOC therapy. Our findings support the use of FEV 1 rate of decline to assess response to SOC therapy and to ensure appropriate assignment of participants with refractory BOS to rescue therapy treatment cohorts.
PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms
Ravindran, Aishwarya , Jiang, Liuyan , Ruan, Gordon , Dasari, Surendra , Abeykoon, Jithma P. , Zanwar, Saurabh , Young, Jason R., Bach, Corrie R. , Ruan, Gordon J , Ravindran, Aishwarya , McConathy, Jonathan , Bennani, N. Nora , Go, Ronald S. , Goyal, Gaurav , Rech, Karen L.

Mayo Clinic

Leukemia & Lymphoma | September 25, 2025 | Volume: 66 | Issue: 14 | Pages: 2675-2684

10.1080/10428194.2025.2561114 | PMID 40995654 Get It

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
McDade, Eric , Barthélemy, Nicolas R. , Wang, Guoqiao , Li, Yan , Cao, Yuchen , Clifford, David B., Goate, Alison , Renton, Alan E., Hassenstab, Jason , Perrin, Richard J. , Xiong, Chengjie , Mummery, Catherine J. , Berman, Sarah , Roberson, Erik D. , Dyck, Christopher van , Gauthier, Serge , Masters, Colin L. , Bittner, Tobias , Yaari, R. , Chhatwal, Jasmeer P. , Chrem, Patricio, Xiong, Chengjie , Ringman, John M. , Ryan, Natalie S. , Day, Gregory S. , Daniels, Alisha , Morris, John C., Supnet, Charlene , Team, The DIAN‐TU Study Team and DIAN Obs, McDade, Eric M , Bateman, Randall J , Roberson, Erik , Day, Gregory S , Masters, Colin L , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Gordon, Brian A. , Benzinger, Tammie L.S. , Renton, Alan , Llibre‐Guerra, Jorge J. , Xiong, Chengjie , Cruchaga, Carlos , Lah, James J. , Masellis, Mario , Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Wallon, David , Ikeuchi, Takeshi , Lee, Jae‐Hong , Roh, Jee Hoon , Schofield, Peter R. , Fox, Nick C. , Vöglein, Jonathan , Karch, Celeste M. , Ibanez, Laura , Sánchez‐Valle, Raquel , Morris, John C. , Levey, Allan I. , Bateman, Randall J. , Team, The DIAN‐TU Study Team and DIAN Obs

Mayo Clinic

Alzheimer's & Dementia | September 23, 2025 | Volume: 21 | Issue: 9 | Pages: No page available

10.1002/alz.70689 | PMID 40985290 Get It

Abstract BACKGROUND Tau‐derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid‐beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long‐term anti‐Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them. METHODS A post‐hoc analysis of the DIAN‐TU‐001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab ( n = 50), gantenerumab ( n = 52), or placebo ( n = 40). High‐resolution mass spectrometry quantified CSF tau species over four years. RESULTS Phosphorylated tau (p‐tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab‐mediated Aβ plaque reduction. Nearly a decade later, MTBR‐tau243 and p‐tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression. DISCUSSION Initially changing soluble p‐tau species track Aβ plaque reduction, while ptau205 and MTBR‐243 reflect tau tangle pathology, informing different pathways of therapeutic strategies. Highlights p‐tau217 and p‐tau231 correlate with Aβ‐PET and respond to Aβ‐plaque lowering therapies. Aβ immunotherapy trials support a direct link between p‐tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT‐related biomarkers. Blood‐based p‐tau217 assays may provide a non‐invasive tool to monitor Aβ therapies. MTBR‐tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT‐targeting therapies.
Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Abdelmoity, Omar , Wisch, Julie K. , Kennedy, James T. , Vlassenko, Andrei G. , Handen, Benjamin L. , Head, Elizabeth , Lai, Florence , Rosas, H. Diana , Hartley, Sigan L. , Tudorascu, Dana , Keefe, Sarah , Ikeuchi, Takeshi, Morris, John C., Roh, Jee Hoon , Day, Gregory S. , Xiong, Chengjie , Head, Elizabeth , Lao, Patrick , Keefe, Sarah , Roh, Jee Hoon , Day, Gregory S , Gordon, Brian A , Xiong, Chengjie , Wisch, Julie K , Goyal, Manu S. , Flores, Shaney , Keator, David B. , Rafii, Michael S. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Fougère, Christian la , Llibre‐Guerra, Jorge J. , Ikeuchi, Takeshi , Morris, John C. , Schofield, Peter R. , Gordon, Brian A. , Benzinger, Tammie L.S. , Ances, Beau M.

Mayo Clinic

Annals of Neurology | September 22, 2025 | Volume: 98 | Issue: 6 | Pages: 1237-1248

10.1002/ana.78002 | PMID 40977577 Get It

Objectives Directly compare the brain glucose patterns seen with [F‐18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD). Methods Cross‐sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within‐group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses. Results Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls ( p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls ( p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive. Interpretation Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG‐PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237–1248